• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感觉好转固然好,但感觉良好更好,尽快且尽可能长时间地感觉良好更好。在 OMERACT 10 会议上的反应标准和变化的重要性。

It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10.

机构信息

Department of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA.

出版信息

J Rheumatol. 2011 Aug;38(8):1720-7. doi: 10.3899/jrheum.110392.

DOI:10.3899/jrheum.110392
PMID:21807792
Abstract

The OMERACT patient reported outcomes (PRO) working group evaluated the methodologies for measuring responsiveness to change at the Outcome Measures in Rheumatology (OMERACT) 10 meeting. The outcome measures used in PRO studies are often expressed as continuous data at the group level (e.g., mean change in pain on a 0-100 visual analog scale). This is difficult to interpret and cannot easily be translated to the individual level of response. When interpreting scores at the individual level, it is important to take into account the following 4 main concepts: (1) improvement; (2) status of well-being; (3) onset of action; and (4) sustainability. Information from clinical trials on how many patients showed a response, what the level of response was, and how many patients are doing well, would be extremely useful for physicians. The objective of this article is to outline how continuous data may be reported in a clinically relevant manner. We will describe 5 techniques of reporting continuous variables in clinical studies and discuss the relevance of each.

摘要

OMERACT 患者报告结局(PRO)工作组在第 10 次结局测量在风湿病学(OMERACT)会议上评估了衡量变化反应的方法学。PRO 研究中使用的结局测量通常以群组水平的连续数据表示(例如,0-100 视觉模拟量表上疼痛的平均变化)。这很难解释,也不容易转化为个体反应水平。在解释个体水平的分数时,需要考虑以下 4 个主要概念:(1)改善;(2)幸福感状态;(3)作用开始;(4)可持续性。关于有多少患者表现出反应、反应水平如何以及有多少患者情况良好的临床试验信息对医生来说将非常有用。本文的目的是概述如何以临床相关的方式报告连续数据。我们将描述临床研究中报告连续变量的 5 种技术,并讨论每种技术的相关性。

相似文献

1
It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10.感觉好转固然好,但感觉良好更好,尽快且尽可能长时间地感觉良好更好。在 OMERACT 10 会议上的反应标准和变化的重要性。
J Rheumatol. 2011 Aug;38(8):1720-7. doi: 10.3899/jrheum.110392.
2
Overview of the patient perspective at OMERACT 10--conceptualizing methods for developing patient-reported outcomes.OMERACT 10 中的患者视角概述——概念化患者报告结局的开发方法。
J Rheumatol. 2011 Aug;38(8):1699-701. doi: 10.3899/jrheum.110388.
3
Patient perspective: choosing or developing instruments.患者视角:选择或开发工具。
J Rheumatol. 2011 Aug;38(8):1716-9. doi: 10.3899/jrheum.110390.
4
Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.开发评估类风湿关节炎 flares 的指标:OMERACT RA Flare Definition 工作组的概念报告。
J Rheumatol. 2011 Aug;38(8):1745-50. doi: 10.3899/jrheum.110400.
5
Measuring functional disability in early rheumatoid arthritis: the validity, reliability and responsiveness of the Recent-Onset Arthritis Disability (ROAD) index.测量早期类风湿性关节炎的功能残疾:近期发病关节炎残疾(ROAD)指数的有效性、可靠性和反应性。
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S31-42.
6
Domains selection for patient-reported outcomes: current activities and options for future methods.患者报告结局测量量表领域选择:当前活动和未来方法选项。
J Rheumatol. 2011 Aug;38(8):1702-10. doi: 10.3899/jrheum.110389.
7
Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis.患者视角:类风湿关节炎中疲劳测量的原因及方法
J Rheumatol. 2007 May;34(5):1171-3.
8
OMERACT 10 Patient Perspective Virtual Campus: valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health.OMERACT 10 患者视角虚拟校园:重视健康;评估类风湿关节炎疲劳、RA 睡眠、关节置换和系统性硬化症的结局;以及健康变化的临床意义。
J Rheumatol. 2011 Aug;38(8):1728-34. doi: 10.3899/jrheum.110393.
9
Patient perspective on remission in rheumatoid arthritis.患者对类风湿关节炎缓解的看法。
J Rheumatol. 2011 Aug;38(8):1735-8. doi: 10.3899/jrheum.110394.
10
The consequences of rheumatoid arthritis: quality of life measures in the individual patient.类风湿关节炎的后果:个体患者的生活质量衡量指标。
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S43-52.

引用本文的文献

1
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.司库奇尤单抗在银屑病关节炎GRAPPA各领域的疗效:3期KEEPsAKE 1和2研究患者的汇总分析
RMD Open. 2025 Aug 25;11(3):e005522. doi: 10.1136/rmdopen-2025-005522.
2
Patient Reported Outcome Measurements in Adult Spinal Deformity: A Narrative Review.成人脊柱畸形患者报告结局测量:一项叙述性综述。
Global Spine J. 2025 Jul;15(3_suppl):87S-94S. doi: 10.1177/21925682231188811. Epub 2025 Jul 9.
3
Variations in quantifying patient reported outcome measures to estimate treatment effect.
在量化患者报告的结局指标以估计治疗效果方面的差异。
World J Methodol. 2025 Jun 20;15(2):97078. doi: 10.5662/wjm.v15.i2.97078.
4
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.口服选择性变构酪氨酸激酶2抑制剂德卡伐替尼治疗活动性系统性红斑狼疮患者:一项II期随机试验中对患者报告结局的疗效
Lupus Sci Med. 2025 Jun 1;12(1):e001517. doi: 10.1136/lupus-2025-001517.
5
Real-world safety and effectiveness of guselkumab in patients with psoriasis: A post-marketing surveillance study through up to week 52 in Japan.古塞库单抗在银屑病患者中的真实世界安全性和有效性:一项在日本进行的长达52周的上市后监测研究。
J Dermatol. 2025 Jun;52(6):967-982. doi: 10.1111/1346-8138.17710. Epub 2025 Mar 29.
6
Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis.将患者报告的结局测量指标相结合,以筛查类风湿关节炎和银屑病关节炎的活动性疾病。
RMD Open. 2024 Oct 18;10(4):e004687. doi: 10.1136/rmdopen-2024-004687.
7
Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials.古塞库单抗早期改善与银屑病关节炎的持续控制相关:两项3期试验的事后分析
Rheumatol Ther. 2024 Dec;11(6):1501-1517. doi: 10.1007/s40744-024-00702-0. Epub 2024 Sep 11.
8
Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.阿达木单抗 - adbm与阿达木单抗参比产品对类风湿关节炎患者报告结局的影响:VOLTAIRE - RA研究结果
Rheumatol Ther. 2024 Oct;11(5):1291-1302. doi: 10.1007/s40744-024-00687-w. Epub 2024 Aug 9.
9
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials.在3期SELECT-PsA 1和2随机对照试验中,银屑病关节炎患者临床疾病控制的达成与患者报告结局及生活质量改善之间的关联
ACR Open Rheumatol. 2024 Nov;6(11):736-745. doi: 10.1002/acr2.11714. Epub 2024 Aug 1.
10
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.乌帕替尼在对生物性改善病情抗风湿药(bDMARDs)难治的类风湿关节炎患者中的安全性和有效性:SELECT-CHOICE研究第216周的结果
Rheumatol Ther. 2024 Oct;11(5):1197-1215. doi: 10.1007/s40744-024-00694-x. Epub 2024 Jul 20.